Skip to main content

Table 2 Outlines of periodic assessments of study participants

From: Cost effectiveness of different screening strategies for gestational diabetes mellitus screening: study protocol of a randomized community non-inferiority trial

 Method or sample used> 14 week14–19 week20–23 week24–30 week31–34 week35–37 week38 week39 week40 weekBirth28 days after birth
 Past medical, reproductive and obstetrics history
 WeightCalibrated scaleaaaaaaaaa  
 Blood pressure (systolic, diastolic)Calibrated mercury sphygmomanometeraaaaaaaaa  
 Fundal heightMeasuring tape aaaaaaaa  
 Fetal heart rate  aaaaaaaa  
 Fetal ultrasound a  a a     
 FPGVenous samplea          
 OGTT-75 g or GCT following OGTT-100 gVenous sample   a       
 Quality of lifeQuestionnaire aaaa a    
 Drug adherenceQuestionnaire aaaa a    
 GDM treatment satisfactionQuestionnaire aaaa a    
 Cost-effectivenessQuestionnaire aaaa a  a 
 Feto-maternal outcomesc          a 
 C-peptideCord sample         a 
 WeightCalibrated baby scale         a 
 Recumbent lengthInfantometer         a 
 Head circumferenceMeasuring tape         a 
 Blood glucoseeHeel-stick sample         a 
 Neonatal outcomesd          aa
  1. aData collected from routine and expert scans that occur during the time points
  2. bIf GDM or other complication were diagnosed, subsequent additional visits, measurements and standard treatment were performed
  3. cFeto-maternal outcomes continuously recoded include abortion, gestational hypertension, pre-eclampsia/eclampsia, preterm birth, instrumental delivery, primary cesarean section, polyhydramnios, oligohydramnios, premature rupture of membrane, placenta Previa, placenta abruption, postpartum hemorrhage, wound and incision infection
  4. dNeonatal outcomes include shoulder dystocia, intrauterine growth restriction, macrosomia, Apgar score, neonatal hypoglycemia, neonatal hypocalcemia, neonatal hyperbilirubinemia, polycythemia, neonatal intensive care unit admission, neonatal care unit admission, Respiratory distress syndrome, congenital anomaly, neonatal asphyxia, intrauterine fetal death, perinatal death, Erb–Duchenne palsy, birth trauma, neonatal sepsis
  5. eMeasured for high risk groups